Since 1996, 23 states and Washington, DC have conceded laws that allow the use of marijuana for a variety of medical conditions, as per the ‘Office of National Drug Control Policy’. However, needless to say that these state laws neither change the fact that using marijuana is an offense under federal law, nor do these state marijuana laws change the criteria or process for FDA approval of safe and effective medications. Nowadays, prescription and monitoring of the medicinal marijuana has turned out to be more skillful. A cannabis inhaler has been created by Syqe Medical, a startup out of Tel-Aviv, Israel.
Syqe Inhaler is a pocket-sized selective-dose drug delivery platform which will allow patients regain quality of life. It makes use of selective 100 microgram dosing precision, real-time thermal and flow controllers, lung interfacing, and wireless connectivity.
This inhaler has been sanctioned by the Israel’s Ministry of Health and is being used for more than a year at Rambam Medical Center in the city of Haifa. This institution has been labeled as the first of its kind in the world by ‘Times of Israel’ for recommending weed as “standard medical treatment.”
Teva and Syqe said in a joint statement:
“The company has completed clinical trials demonstrating the inhaler’s precision and compliance with pharmaceutical standards. In addition, the medical technology of Syqe only modifies the physical structure of the plant. Thereby enabling safe, precise and measurable delivery by inhalation.”
Furthermore, the platform is comprised of proprietary raw drug Structural Modification methods. Besides, Syqe also includes uniquely identified preloaded cartridges. In addition to all this, the linked clinical database will prove to be of great help to physicians, researchers and healthcare entities. According to Syqe,
“This new level of precision will allow patients to reach the coveted optimum balance between symptom relief and psychoactivity, regaining their quality of life.”
The inhaler that has been created by means of 3D-printing technology is available in two variations. The first variation is for individuals and the other is for medical institutions. ‘Syqe inhaler Exo’ is the hospital version and it consists of a caregiver interface and allows for remote dosing. Exo is used in pain clinics, cancer centers, intensive care units, and other medical institutions. Currently, the Syqe Inhaler Exo is available for hospital use in Israel.
The health ministry has allowed the cannabis inhalers for widespread use with medical marijuana patients, as per a statement made by Teva and Syqe. Moreover, the Teva and Syqe hope that Israel’s medical-marijuana licenses will double by 2018.
This progress would have great health advantages owing to around 26,000 medical-marijuana users in Israel. As per now, the medical users are also consuming carcinogens while smoking their medicine. Syqe settles this problem by providing the inhalers with an added benefit of discretion.
Eytan Hyam, Syqe Medical chairman told:
“For doctors, the inhaler solves the problem of prescribing plants for smoking and offers a solution for patients. For the first time, they will be able to receive a precise dose of medical cannabis.”
Director of the Pain Research Department at Rambam Medical Center, Israel, Elon Eisenberg said:
“The extent of medical cannabis usage for the treatment of pain and other symptoms has increased significantly in recent years. The advancement of this inhaler fulfills our greatest aspirations, to be able to administer accurate and reliable doses of cannabis. It’s a headway in cannabis treatment and the medical use of cannabis in Israel and around the world.”